Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects
2006
The effect of long-chain n-3 PUFA on the metabolism of apoB100-containing lipoprotein in diabetic subjects is not fully understood. The objective of the present study was to determine the effect of a daily intake of 1080 mg EPA and 720 mg DHA for diabetic subjects on the kinetics of apoB100-containing lipoprotein in the fasting state. A kinetic study was undertaken to determine the mechanisms involved in the effects of n-3 fatty acids in terms of a decrease in triacylglycerol level in type 2 diabetic patients. We have studied the effect of fish oils on the metabolism of apoB100 endogenously labelled by 5,5,5-2H3-leucine in type 2 diabetic patients in the fasting state. The kinetic parameters of apoB100 in VLDL, intermediate-density lipoprotein and LDL were determined by compartmental modelling in five diabetic subjects before and 8 weeks after n-3 fatty acid treatment. Treatment did not change the plasma cholesterol level (0.801 (SD 0.120) v. 0.793 (SD 0.163) mmol/l) but lowered the plasma triacylglycerol level (1.776 (SD 0.280) v.1.356 (SD 0.595) mmol/l; P<0.05). Treated patients showed a decrease in VLDL apoB100 concentration (0.366 (SD 0.030) v.0.174 (SD 0.036) g/l; P<0.05) related to a decrease in VLDL 1 production (1.49 (SD 0.23) v.0.44 (SD 0.19) mg/kg per h; P<0.05) and an increase in the VLDL conversion rate (0.031 (SD 0.024) v.0.052 (SD 0.040) per h; P<0.05), with no change in fractional catabolic rates. Treatment led to a higher direct production of intermediate-density lipoprotein (0.02 (SD 0.01) v.0.24 (SD 0.12) mg/kg per h; P<0.05). In conclusion, the present study, conducted in the fasting state, showed that supplementation with n-3 fatty acids in type 2 diabetic patients induced beneficial changes in the metabolism of apoB100-containing lipoprotein.
显示更多 [+] 显示较少 [-]